---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-106030"
form_type: "8-K"
ticker: "HEPA"
cik: "0001583771"
company_name: "Hepion Pharmaceuticals, Inc."
filed_at: "2023-10-03T23:59:59+00:00"
generated_at: "2026-06-10T05:31:05.362120+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Hepion Pharmaceuticals raises $5.0M in registered direct offering with warrants

## Summary
- Gross proceeds $5.0M from sale of 980,393 shares (or equivalents) at $5.10/share plus warrants.
- Series A and B warrants to buy up to 980,393 shares each at $4.85; Series A expires in 5 yrs, Series B in 1.5 yrs.
- Closing expected on or about Oct 3, 2023; A.G.P./Alliance Global Partners as placement agent.
- Net proceeds intended for clinical development and working capital.

## SEC filing metadata
- accession: 0001104659-23-106030
- form_type: 8-K
- ticker: HEPA
- cik: 0001583771
- company_name: Hepion Pharmaceuticals, Inc.
- filed_at: 2023-10-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583771/000110465923106030/0001104659-23-106030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583771/000110465923106030/tm2327415d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-106030
- JSON: https://secwatch.observer/filing/0001104659-23-106030.json
- Plain text: https://secwatch.observer/filing/0001104659-23-106030.txt

## Key facts
- Material Agreements
  Hepion Pharmaceuticals, Inc. entered into Purchase Agreement with an institutional investor valued at approximately $5.0 million (effective 2023-09-28).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an institutional investor
  - Value: approximately $5.0 million
  - Effective: 2023-09-28
  source text: On September 28, 2023, Hepion Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor, pursuant to which the Company agreed to issue and sell to such investor, in a registered direct offering (i) 400,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at a purchase price of $5.10 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 580,393 shares of the Company’s Common Stock at an exercise price of $0.0001 per share at an offering price of $5.09 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583771/000110465923106030/0001104659-23-106030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.